ImmuPharma PLC (LON:IMM) said a period of exclusivity has run out between it and Incanthera Limited, which allows the ImmuPharma to discuss collaborations with other potential partners for its Nucant cancer programme.
“Notwithstanding the expiry of the exclusivity period, discussions with Incanthera are continuing in good faith for broader collaboration,” the AIM-listed life sciences group told investors.
“There can be no guarantee that any agreement will be reached with Incanthera on a broader collaboration.”
An outline deal was inked last September, at which point ImmuPharma took a £2mln stake in Incanthera. The deadline for a definitive agreement was extended from the end of December to the end of March.